The article discusses the challenges faced by pharmaceutical companies in emerging markets as the global pharmaceutical industry continues to evolve. It states that emerging markets face difficulties in adopting the western regulatory concepts of quality and compliance because of their regulatory framework. ...
Synthetic biology is increasingly serving humanity for instance by accelerating the development of new medical treatments and by assisting in the combating of climate change. The Synbio Powerhouse ecosystem managed by VTT offers the key to success.
The use of AI in drug discovery has enabled the exploration of vast chemical space, leading to the discovery of novel drug candidates, some of which have already entered clinical trials. The ability to identify promising compounds more efficiently is a game changer for the pharmaceutical industry....
The stiff regulatory requirements and lack of clarity on several aspects of the regulation made conducting regulatory trials a herculean task. The subsequent expression of great concern by the academic community and the pharmaceutical industry led to rationalization of the regulatory framework that has be...
What are some of the main challenges faced by pharmaceutical and biotechnology companies that are developing new cancer drugs and treatments? In the not-so-distant past, cancer represented an enormous unmet medical need, mostly because there weren’t many effective drugs or treatment options for var...
This year the pharmaceutical industry in the UK (and notably its sales arm) has dominated headlines, with recent scrutiny of sales practices both here and abroad damaging the reputation of the industry. This is compounded by the recent bad press across the industry, the...
pharma industry. However, in 2020, pharmaceutical leaders realize that approach is no longer sufficient enough. In addition, pharmaceutical data breaches continue to increase by the day, therefore the need to take action is clear. There are a number of challenges to overcome within the industry. ...
Biopharmaceuticals could become the core of the pharmaceutical industry, but not without significant transformation in the laboratory and in strategy, technology, and operations.
He challenges the cancer research industry as absorbing much monies with relatively little return as well as the entire pharmaceutical sector, part of the medical industrial complex that is best understood as an vested interest with a primary focus on generating profit, lets call it what it is pl...
Yet, this is a common problem faced in the pharmaceutical industry. According to the World Health Organization (WHO) data, up to ten percent (10%) of drugs in circulation worldwide are counterfeit, and this number is said to be even much higher (up to 30%) in developing countries (...